Notice is hereby given that, on April 4, 2003, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (“the Act”), Inter Company Collaboration for AIDS Drug Development (“the Collaboration”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership status. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, although there are no other changes in the membership, Collaboration member Gilead Sciences, Inc. of Foster City, CA, has acquired Collaboration member Triangle Pharmaceuticals, Inc. of Durham, NC by merging Triangle with a wholly-owned subsidiary of Gilead.
No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and Inter Company Collaboration for AIDS Drug Development intends to file additional written notification disclosing all changes in membership.
On May 27, 1993, Inter Company Collaboration for AIDS Drug Development filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to section 6(b) of the Act on July 6, 1993 (58 FR 36223).
The last notification was filed with the Department on November 8, 2001. A notice was published in the Federal Register pursuant to section 6(b) of the Act of February 15, 2002 (67 FR 7201).Start Signature
Constance K. Robinson,
Director of Operations, Antitrust Division.
[FR Doc. 03-12219 Filed 5-15-03; 8:45 am]
BILLING CODE 4410-11-M